On Multiobjective Evolution Model

Self-Organized Criticality (SOC) phenomena could have a significant effect on the dynamics of ecosystems. The Bak-Sneppen (BS) model is a simple and robust model of biological evolution that exhibits punctuated equilibrium behavior. Here we will introduce random version of BS model. Also we generalize the single objective BS model to a multiobjective one.Comment: 6 pages, 5 figure

Physical Multi-Layer Phantoms for Intra-Body Communications

This paper presents approaches to creating tissue mimicking materials that can be used as phantoms for evaluating the performance of Body Area Networks (BAN). The main goal of the paper is to describe a methodology to create a repeatable experimental BAN platform that can be customized depending on the BAN scenario under test. Comparisons between different material compositions and percentages are shown, along with the resulting electrical properties of each mixture over the frequency range of interest for intra-body communications; 100 KHz to 100 MHz. Test results on a composite multi-layer sample are presented confirming the efficacy of the proposed methodology. To date, this is the first paper that provides guidance on how to decide on concentration levels of ingredients, depending on the exact frequency range of operation, and the desired matched electrical characteristics (conductivity vs. permittivity), to create multi-layer phantoms for intra-body communication applications

Macrophage migration inhibitory factor (MIF) in the development and progression of pulmonary arterial hypertension.

Macrophage migration inhibitory factor (MIF) has been described as a pro-inflammatory cytokine and regulator of neuro-endocrine function. It plays an important upstream role in the inflammatory cascade by promoting the release of other inflammatory cytokines such as TNF-alpha and IL-6, ultimately triggering a chronic inflammatory immune response. As lungs can synthesize and release MIF, many studies have investigated the potential role of MIF as a biomarker in assessment of patients with pulmonary arterial hypertension (PAH) and using anti-MIFs as a new therapeutic modality for PAH